FDA approved fused-pyrimidines as potential PI3K inhibitors: a computational repurposing approach-Reference-Cited by-同舟云学术

FDA approved fused-pyrimidines as potential PI3K inhibitors: a computational repurposing approach

Published:2023-11 Issue: Volume: Page:1-18
ISSN:0739-1102
Container-title:Journal of Biomolecular Structure and Dynamics
language:en
Short-container-title:Journal of Biomolecular Structure and Dynamics

Author:

Vishwakarma Pinky¹,Siddiqui Noor Fatima¹,Thakur Shikha¹,Jadhav Hemant¹

Affiliation:

1. Pharmaceutical Chemistry Laboratory, Department of Pharmacy, Birla Institute of Technology and Sciences Pilani, Pilani, Rajasthan, India

Publisher

Informa UK Limited

Subject

Molecular Biology,General Medicine,Structural Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07391102.2023.2276315

Reference42 articles.

1. Altschul, S. F., & Pop, M. (2017, July 9). Sequence alignment. In Rosen, K. H., Shier, D. R., Goddard, W. (Eds.), Statistics in human genetics and molecular biology (pp. 125–138). Taylor & Francis.

2. Synthesis, in-Silico studies and biological evaluation of pyrimidine based thiazolidinedione derivatives as potential anti-diabetic agent

3. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

4. The regulation and function of Class III PI3Ks: novel roles for Vps34

5. PI3K inhibitors as potential therapeutics for autoimmune disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17

2. Synthesis of ciprofloxacin-linked 1,2,3-triazole conjugates as potent antibacterial agents using click chemistry: exploring their function as DNA gyrase inhibitors via in silico- and in vitro-based studies;RSC Advances;2024